Back to Authors

Pavlisko, Elizabeth N.

https://orcid.org/0000-0001-9598-3369

Mayo Clinic

Duke Medical Center

Citations 2

Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group
Husain, Aliya N. , Chapel, David B. , Attanoos, Richard , Beasley, Mary Beth , Butnor, Kelly J. , Đačić, Sanja , Hiroshima, Kenzo , Hung, Yin P. , Klebe, Sonja , Krausz, Thomas, Khoór, András , Litzky, Leslie A., Nabeshima, Kazuki , Roden, Anja C. , Roggli, Victor L., Schulte, Jefree J. , Sheaff, Michael , Walts, Ann E. , Colby, Thomas V. , Hung, Yin P , Brčić, Luka , Chirieac, Lucian R. , Churg, Andrew , Marchevsky, Alberto M. , Nicholson, Andrew G. , Pavlisko, Elizabeth N. , Sauter, Jennifer L. , Travis, William D. , Tsao, Ming‐Sound

Archives of Pathology & Laboratory Medicine | April 8, 2024 | Volume: 148 | Issue: 11 | Pages: 1251-1271

10.5858/arpa.2023-0304-ra Get It

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.— There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.
Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters
Mujahed, Tala , Tazelaar, Henry D. , Sukov, William R. , Halling, Kevin C. , Davila, Jaime , Glass, Carolyn , Pavlisko, Elizabeth N. , Strickland, Kyle C. , Roggli, Victor L., Haque, Monira , Mneimneh, Wadad , Carter, Elliot, Garcia‐Kennedy, Richard, Larsen, Brandon T. , Davila, Jaime I, Davila, Jaime I , Tazelaar, Henry D. , Galateau-Sallé, Françoise , Glidden, David V.

American Journal of Surgical Pathology | August 21, 2020 | Volume: 45 | Issue: 2 | Pages: 255-262

10.1097/pas.0000000000001574 Get It

Only 50% to 70% of patients with mesothelioma report asbestos exposure. Other exposures (eg, radiation) play a role in some cases, but some patients have no obvious cause. We describe a series of patients with long-standing indwelling intra-abdominal shunt catheters who developed malignant peritoneal mesothelioma, suggesting a novel association. We identified 7 patients who had shunts and subsequently developed mesothelioma (5 women; median age: 31 y, range: 18 to 45 y). Clinical history and pathology materials were reviewed, and RNA sequencing was performed. Clinical presentations varied; 6 patients had hydrocephalus and a ventriculoperitoneal shunt, and 1 patient had portal hypertension and a portoatrial shunt. The median duration of shunt therapy in 5 cases was 29 years (range: 12 to 35 y); the remaining 2 patients also had shunts for many years, but specific details were unavailable. Two patients had radiotherapy for malignancies in childhood. One had an alleged exposure to asbestos and 1 had prior exposure to talc. The rest had no known risk factors. Histologically, all tumors were purely epithelioid. Treatments included surgical debulking, chemotherapy, and palliative care. All 7 died of disease (median survival: 7 mo, range: 1 to 18 mo). Molecular testing showed loss of NF2 and CDKN2A/B and a BAP1 mutation in 1 case, and no genomic alterations associated with mesothelioma in 2 cases. Peritoneal mesothelioma may represent a complication of long-standing indwelling shunt catheters. The mechanism is unknown, but chronic peritoneal irritation may play a role. Albeit rare, mesothelioma should be considered in patients with a shunt who present with new ascites.